2022
IMPACT trial by IMCYSE completed recruitment
MELD-ATG trials opened for a younger cohort of people with newly diagnosed type 1 diabetes, ages 5 to 25.
2022
IMPACT trial by IMCYSE completed recruitment
MELD-ATG trials opened for a younger cohort of people with newly diagnosed type 1 diabetes, ages 5 to 25.
2022
IMPACT trial by IMCYSE completed recruitment
MELD-ATG trials opened for a younger cohort of people with newly diagnosed type 1 diabetes, ages 5 to 25.
Our founders
Eu facilisis sed odio morbi quis commodo. Urna nunc id cursus metusenectus et netus et malesuada fames ac. Magna sit amet purus gravida quis blandit turpis cursus inuis imperdiet massa tincidunt nunc.
INNODIA launch supported by:
Magna ac placerat vestibulum lectus
Lorem ipsum dolor sit, adipiscing consectetur elitunc maxi musnulla ut commodo sagittis.